New insider activity at Amylyx Pharmaceuticals Inc ( (AMLX) ) has taken place on December 3, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CMO Camille Bedrosian has recently sold 6,580 shares of Amylyx Pharmaceuticals Inc stock, amounting to a total transaction value of $94,357.
Recent Updates on AMLX stock
Amylyx Pharmaceuticals Inc. has seen recent positive developments, particularly in its financial performance and strategic initiatives, which have influenced analysts to raise their price targets. Mizuho and H.C. Wainwright have both increased their price targets following the company’s strong Q3 2025 results, which highlighted a significant reduction in net loss and a robust cash position, extending their runway into 2028. The positive outlook is further supported by the progress in the LUCIDITY trial for avexitide, despite a delay in enrollment completion to Q1 2026. The enthusiasm for avexitide is driven by its potential as the first therapy for post-bariatric hypoglycemia (PBH), a market with substantial unmet needs. Additionally, the FDA breakthrough therapy designation for avexitide underscores its potential impact. The company’s strategic focus remains on the potential approval and commercialization of avexitide by 2027, while advancing its pipeline for other neurodegenerative and endocrine disorders.
Spark’s Take on AMLX Stock
According to Spark, TipRanks’ AI Analyst, AMLX is a Neutral.
Amylyx Pharmaceuticals’ overall stock score is primarily impacted by its financial challenges, including declining revenues and operational losses. The technical analysis shows some short-term bullish momentum, but the valuation remains unattractive due to negative earnings. The earnings call provides a positive outlook with a strong cash position and progress in drug development, although delays in key trials present risks.
To see Spark’s full report on AMLX stock, click here.
More about Amylyx Pharmaceuticals Inc
YTD Price Performance: 251.66%
Average Trading Volume: 1,761,439
Technical Sentiment Signal: Buy
Current Market Cap: $1.51B